Diabetics with kidney failure should not lower their blood glucose levels as much as diabetics without kidney failure, two separate studies presented during the American Society of Nephrology''s Annual Kidney Week have stressed.
For most patients with diabetes, taking medication to lowering blood levels of hemoglobin A1C, which reflect average blood glucose levels, to <7% can lower their risk of developing certain complications. Sylvia Paz Ramirez, MD (Arbor Research Collaborative For Health) and her colleagues wondered whether this holds true for diabetic patients who have developed kidney failure.
The researchers analyzed data from 8,437 dialysis patients from 12 countries who had diabetes. They found that the lowest risk of death during the study occurred when hemoglobin A1C levels were between 7% and 8%. Both high and low levels were linked with increased rates of death, particularly for patients with levels of 9% or higher or less than 5%. Among patients with A1C levels below 7%, death rates were higher among patients taking diabetes medications.
In a similar study, Miklos Molnar MD, PhD (Semmelweis University, in Budapest, Hungary) and his team examined death rates among 54,757 diabetic patients treated at DaVita dialysis clinics from July 2001 through June 2006 with follow-up through June 2007. They found a link between high death rates and hemoglobin A1C levels of 8% or greater. Very low levels also increased patients'' risk of dying during the study.
These results indicate that unlike for most patients with diabetes, diabetics with kidney failure benefit the most when their hemoglobin A1C levels are between 7% and 8%, although clinical trials are needed to definitely determine the optimal range.
Study authors for "Hemoglobin A1C Levels and Mortality in the ESRD Population: Findings from the DOPPS" (abstract TH-OR065) include Sylvia Paz Ramirez, MD, Jyothi Thumma, Francesca Tentori, MD, Brenda Gillespie, PhD, Masaaki Inaba, MD, PhD, Robert Nelson, MD, PhD, Ronald Pisoni, PhD, and Bruce Robinson, MD.
Study authors for "Glycemic Control and Mortality in Hemodialysis Patients with Diabetes Mellitus: A Six Year Cohort Study" (abstract TH-OR085) include Miklos Molnar, MD, PhD, Joni Ricks, Csaba Kovesdy, MD, Anuja Shah, MD, Allen Nissenson, MD, Mark Williams, MD, and Kamyar Kalantar-Zadeh, MD, PhD.
Disclosures available at http://www.asn-online.org/press/
ASN Kidney Week 2011, the largest nephrology meeting of its kind, will provide a forum for 13,000 professionals to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2011 will take place November 8 - November 13 at the Pennsylvania Convention Center in Philadelphia, PA.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.